Navigation Links
Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
Date:10/9/2009

statements that reflect Soligenix, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates," "believes," "intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. Soligenix cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including SGX201, orBec® and LPM(TM), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec® for gastrointestinal GVHD include the risks that: the FDA's requirement that Soligenix conduct additional clinical trials to demonstrate the safety and efficacy of orBec
'/>"/>
SOURCE Soligenix, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Medelis Expands CRO Services to Medical Devices, Appoints Dr. Inder Makin as VP
3. Micromet Appoints Former Roche Oncology Clinical Leader Jan Fagerberg as Chief Medical Officer
4. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
5. BioNanomatrix Appoints Genomic Research Experts Charles Lee and David L. Barker as Advisers
6. Ironwood Appoints Thomas McCourt As Chief Commercial Officer and Senior Vice President of Marketing and Sales
7. Seambiotic Appoints New CEO
8. Spherix Incorporated Appoints Dr. Ram Nimmagudda As Director of New Business Development
9. Cylex, Inc. Appoints Brad L. Stewart as Chief Executive Officer and Chairman of the Board
10. ABRISA Appoints Jim Veler as President/CEO
11. PharmaVentures Corporate Advisory Appoints Nikki Watkins as Practice Head, Product & Portfolio Strategy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... September 17, 2014 Shimadzu ... Liquid Chromatograph (2D-LC), which offers a powerful ... matrices. The system provides a new level ... which is beneficial to scientists analyzing pharmaceutical ... natural products. , Comprehensive 2D-LC combines two ...
(Date:9/17/2014)... September 17, 2014 Immunomic Therapeutics, Inc. ... Research (SBIR) grant to support the continued preclinical development ... ITI with approximately $255,000 over one year to conduct ... of food allergy, affect over one million Americans and ... allergy. Tree nut exposure is also a risk for ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - SQI Diagnostics ... that develops and commercializes proprietary technologies and products for ... have been approved for trading in the ... Trading is expected to commence on September 17, 2014 ... will continue to trade on the TSX Venture Exchange ...
(Date:9/17/2014)... Angeles, CA (PRWEB) September 17, 2014 Escape ... microchip for pets which will alert owners if their pet ... using GPS from an implanted microchip in the pet’s body. ... implantable microchips for pets have been around for many years, ... and are not able to track a pet’s location or alert ...
Breaking Biology Technology:Shimadzu’s New Nexera-e Two Dimensional Comprehensive Liquid Chromatograph Empowers Laboratories to Separate Even the Most Complex Mixtures 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 2Immunomic Therapeutics Awarded SBIR Grant to Develop Multi-Nut Allergy Immunotherapy 3SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 2SQI Diagnostics to begin Trading on the OTCQX Marketplace in the United States 3Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 2Implantable Microchip for Pets with GPS Tracking - Patent Filed by Escape Alert, LLC. 3
... CROSSE, Wis., Dec. 8, 2011  Prem Rabindranauth, MD, a heart ... in La Crosse, Wis., is using an exciting ... perform heart bypass surgery. To perform MICS, a very small ... cut through the breast bone that is needed with traditional ...
... WaferGen Biosystems, Inc. (OTCBB:WGBS), an emerging genomic analysis ... its corporate presentation at the Oppenheimer 22nd Annual Healthcare ... 2011. The Company is scheduled to present ... Time.  The presentation will be webcast live and will ...
... Therapies, Inc. (OTCQB: BRTX) ("BRT") today announced that it ... University of Utah.  Pursuant to the agreement, the University ... derived from stem cells. The agreement ... strategic collaboration between BRT and the University of Utah, ...
Cached Biology Technology:Gundersen Lutheran Offers Heart Surgery with Less Pain, Faster Recovery 2WaferGen to Present Corporate Overview at Oppenheimer Healthcare Conference 2BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah 2
(Date:9/17/2014)... Evolution and Yale University offers compelling support for the ... partially predict the likelihood of being diagnosed with mental ... life. The study analyzed medical records of 1.75 million ... 30 years, and adjusted for almost all other known ... Proceedings of the Royal Society, London B . ...
(Date:9/17/2014)... at the Catalan Institute of Oncology-Bellvitge Biomedical Research ... 5 genes differentially expressed in normal accompanying cells ... be used to classify colorectal tumors, predict the ... clinical decisions to prevent relapses. , Biomarkers ... common in our population considering both sexes. About ...
(Date:9/17/2014)... on a Carnegie expedition in Australia,s Great Barrier Reef ... since the mid-1970s. The scientists suggest that ocean acidification ... slowdown. , In a quest for historical context ... current measurements of the growth rate of a section ... more than 30 years ago. Their work is published ...
Breaking Biology News(10 mins):Size at birth affects risk of adolescent mental health disorders 2Size at birth affects risk of adolescent mental health disorders 3Five genes to predict colorectal cancer relapses 2Coral growth rate plummets in 30-year comparison 2
... clinical trial to test a revolutionary treatment for blindness ... (University College London). The trial, funded by the Department ... could have a significant impact on future treatments for ... and children who have a condition called Leber’s congenital ...
... are an integral part of African culture, one of ... South Africa, 21st century drug therapy is used side-by-side ... plants have been used in African medicine to treat ... of the purported benefits of many plants is still ...
... brain study, even people who seemed resilient but were close to ... 11, 2001, have brains that are more reactive to emotional stimuli ... is the finding of a new Cornell study that excluded people ... (PTSD) or major depression. One of the first studies to look ...
Cached Biology News:First clinical trial of gene therapy for childhood blindness 28 plants from South Africa may hold potential for treating high blood pressure 28 plants from South Africa may hold potential for treating high blood pressure 38 plants from South Africa may hold potential for treating high blood pressure 4Traumas like Sept. 11 make brains more reactive to fear 2
This monoclonal antibody specifically recognizes Y. pestiscapsular F1 antigen. It does not cross-react with Y. pseudotuberculosisor Y. enterocolitica....
... Abpromise for all tested applications). ... to KLH derived from within residues 400 ... acid sequence is proprietary)(Peptide available as ... ID: 55693 Swiss ...
Perm/Wash Buffer 250 Tests...
Mouse monoclonal to OCIL ( Abpromise for all tested applications)....
Biology Products: